Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem
Executive Summary
US FDA should create a policy to help save troubled studies, because failure can kill generic development programs, Lachman Consultants’ Michelle Ryder suggests.
You may also be interested in...
GDUFA Research Impacting Generic Development, ANDA Approvals
Increases in approved ANDAs that were affected by GDUFA research shows the importance of the US FDA’s regulatory science program.
GDUFA Research Impacting Generic Development, ANDA Approvals
Increases in approved ANDAs that were affected by GDUFA research shows the importance of the US FDA’s regulatory science program.
Complex Generics: Pre-Competitive Research Collaborations To Get US FDA Funding Boost
Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.